The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F).
about
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agentsNew Therapeutic Approaches in Polycythemia VeraClinical potential of pacritinib in the treatment of myelofibrosisTargeting JAK2 in the therapy of myeloproliferative neoplasmsNovel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera.Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms.AKT is a therapeutic target in myeloproliferative neoplasmsPleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19bCo-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasmsChronic myeloproliferative neoplasms: a collaborative approach.The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML.Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancerHDAC inhibition in lupus models.The oral histone deacetylase inhibitor ITF2357 reduces cytokines and protects islet β cells in vivo and in vitro.The synthetic α-bromo-2',3,4,4'-tetramethoxychalcone (α-Br-TMC) inhibits the JAK/STAT signaling pathway.Efficacy of vorinostat in a murine model of polycythemia veraEpigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies.Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates.Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disordersJAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment.Update on JAK2 Inhibitors in Myeloproliferative NeoplasmHistone deacetylase inhibitors (HDACIs): multitargeted anticancer agentsAnti-inflammatory Agents: Present and FutureAdvances in myelofibrosis: a clinical case approach.Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives.Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells.Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues.Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinasesTreatment options for essential thrombocythemia and polycythemia vera.Deactylase inhibition in myeloproliferative neoplasms.Janus kinase 2 inhibitors in myeloproliferative disorders.The role of HDACs inhibitors in childhood and adolescence acute leukemias.Therapeutic approaches in myelofibrosis.JAK2 inhibition for the treatment of hematologic and solid malignancies.BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques.Emerging targeted therapies in myelofibrosis.Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.Emerging drugs for the treatment of myelofibrosis.Givinostat, a type II histone deacetylase inhibitor, induces potent caspase-dependent apoptosis in human lymphoblastic leukemia.
P2860
Q21198868-B0BC530D-E99E-40B5-AFDA-EDCE790DCD34Q26795677-41742AC9-FE4D-4433-AC78-211ABB3B629AQ26796450-E0A988D7-CB96-4EBC-82F3-989A85AFDE2CQ26860796-63097A41-8667-4C3E-973F-B9DB79064A64Q27687464-955180D5-62D1-4395-992A-3E76E7951FE5Q33398180-41E491A6-0D06-4E9D-9DBD-3CACC16808E3Q33409340-546B9FAF-CA04-45D9-B140-7BE7D1F9D39DQ33623277-3F63E800-3128-4710-BC9E-964A224A2778Q33632244-C19D8A3F-F356-4ABE-A791-3FB3B625D9DBQ33982315-C789741F-362F-4D66-B567-2C75BB1EF615Q34549335-95BF736C-6DC9-450B-9FDA-234DD34FAD76Q34640790-2A349341-D0E3-4509-B632-6F8B3ED3972BQ35016934-6C2358A4-D0BC-4D8B-83B1-7528BAE898E8Q35016981-8CBE8FC6-2A67-4553-A4BE-99A62D5FEAA8Q35017018-26F602FF-531B-4181-8CDF-F077C7080FD0Q35111380-A04A833D-DC1E-4960-9A8B-A3440F487C7BQ35909673-1F2A4ABC-72FE-45E9-9174-A526FB39ACD2Q36001930-FB945236-585D-4376-AB35-A1AEEEA285EDQ36372894-0046FDF9-C7D8-4972-B2BE-4F5F651782CFQ36374813-748683D6-2C0B-468D-94B2-32541531C5B3Q36612537-9CFD7F62-AAED-4079-BBE2-151C21321B30Q36612569-8C51A2B5-DEBB-4220-A1CE-262797985F0DQ36645808-BE004190-FC8A-44F0-AE6A-0A8262D75948Q37118156-E3A4F571-DA11-4CE9-AAD5-728DE14EE5F1Q37212674-67F28DA4-EDFE-4E6F-B335-ADF3F28E7008Q37310619-798AA592-EEFE-4B3E-ABE5-B6AD2A606979Q37460337-7BA77E60-1246-4AC9-831F-63CBD5BCD7EBQ37566249-AB691AF0-D197-4BC3-B592-0CDFD830A9D5Q37687519-F2C30DE5-793F-450F-AD33-F2F5E43A687BQ37810107-1B510889-B3E7-40AC-B49B-CA3D51CD0CD3Q37815421-25579DDD-1762-4696-9A87-AC15D0C624F9Q37815509-081315AC-0457-43B8-A7B1-39129F342949Q37841146-045FA5C8-D15A-4A5E-9464-9C58854456C2Q37860336-3F8453FE-02C5-4F86-AB3F-48E748857D9CQ38001733-43D10782-D6BC-44F0-998F-291CB9F932B2Q38014534-F2246F41-4778-4630-9E61-71E26573880CQ38025160-4CD85D6F-96F9-4B5E-8AD7-F95B1020AF4DQ38081267-12771ADC-394C-4A45-BF36-D3B4A89C4916Q38543775-33508E80-53B1-4C18-8630-B7E39F7B5E1EQ38723094-44AF7C81-F609-4DBB-A1E5-ED73E748E65D
P2860
The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F).
description
2007 nî lūn-bûn
@nan
2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2
@nl
The histone deacetylase inhibi ...... s bearing mutated JAK2(V617F).
@ast
The histone deacetylase inhibi ...... s bearing mutated JAK2(V617F).
@en
type
label
The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2
@nl
The histone deacetylase inhibi ...... s bearing mutated JAK2(V617F).
@ast
The histone deacetylase inhibi ...... s bearing mutated JAK2(V617F).
@en
prefLabel
The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2
@nl
The histone deacetylase inhibi ...... s bearing mutated JAK2(V617F).
@ast
The histone deacetylase inhibi ...... s bearing mutated JAK2(V617F).
@en
P2093
P2860
P356
P1433
P1476
The histone deacetylase inhibi ...... s bearing mutated JAK2(V617F).
@en
P2093
A Carobbio
A Rambaldi
C Dellacasa
O Spinelli
P2860
P2888
P304
P356
10.1038/SJ.LEU.2405049
P577
2007-12-13T00:00:00Z
P5875
P6179
1014001153